Sodium/Glucose Cotransporter-2 Inhibitors (SGLT2i) Therapy in Duchenne Cardiomyopathy
Recruiting · NCT07172971 · Interventional (participants receive a specific treatment) · Lead sponsor: Vanderbilt University Medical Center
View the official record on ClinicalTrials.gov →Interventions studied
What this trial is about
This is a pharmacokinetic study (PK Study) to better understand empagliflozin dosing in pediatric Duchenne muscular dystrophy patients. Empagliflozin is currently used off-label in this population due to the mortality benefits seen in adult cardiomyopathy and heart failure. Investigators will perform PK studies in DMD patients of various ages and weights to better understand the PK profile (absorption, distribution, metabolism, excretion) and dosing to better treat Duchenne cardiomyopathy.
Who can take part
Age range
8 Years to 18 Years
Sex
Male
Healthy volunteers
No - a diagnosis or condition is required
Phase
Phase 1
Study type
Interventional (participants receive a specific treatment)
Inclusion criteria
- Clinical phenotype of DMD confirmed with muscle biopsy or genotype
- Presence of late gadolinium enhancement (LGE) imaging by CMR
- Either normal or mildly depressed systolic function (LVEF\>40%)
- ≥8 years old and ≤18 years old
Exclusion criteria
- Current investigational therapy that may affect cardiovascular function
- Additional genetic or congenital abnormality that may affect cardiovascular function or progression
- Contraindication to or inability to undergo CMR
- Symptomatic heart failure
- History of ketoacidosis or hypersensitivity to SGLT2i therapy
- Type 1 diabetes
- Renal disease or history of frequent urinary tract infections or genitourinary skin infections
Where it is running
1 location listed across 1 US state.
- Vanderbilt University Medical Center - Nashville, Tennessee, United States